Literature DB >> 25867845

In vivo, percutaneous, needle based, optical coherence tomography of renal masses.

Peter G Wagstaff1, Abel Swaan2, Alexandre Ingels3, Patricia J Zondervan3, Otto M van Delden4, Dirk J Faber2, Ton G van Leeuwen2, Jean J de la Rosette3, Daniel M de Bruin5, M Pilar Laguna Pes3.   

Abstract

Optical coherence tomography (OCT) is the optical equivalent of ultrasound imaging, based on the backscattering of near infrared light. OCT provides real time images with a 15 µm axial resolution at an effective tissue penetration of 2-3 mm. Within the OCT images the loss of signal intensity per millimeter of tissue penetration, the attenuation coefficient, is calculated. The attenuation coefficient is a tissue specific property, providing a quantitative parameter for tissue differentiation. Until now, renal mass treatment decisions have been made primarily on the basis of MRI and CT imaging characteristics, age and comorbidity. However these parameters and diagnostic methods lack the finesse to truly detect the malignant potential of a renal mass. A successful core biopsy or fine needle aspiration provides objective tumor differentiation with both sensitivity and specificity in the range of 95-100%. However, a non-diagnostic rate of 10-20% overall, and even up to 30% in SRMs, is to be expected, delaying the diagnostic process due to the frequent necessity for additional biopsy procedures. We aim to develop OCT into an optical biopsy, providing real-time imaging combined with on-the-spot tumor differentiation. This publication provides a detailed step-by-step approach for percutaneous, needle based, OCT of renal masses.

Entities:  

Mesh:

Year:  2015        PMID: 25867845      PMCID: PMC4401379          DOI: 10.3791/52574

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  15 in total

1.  High-speed optical frequency-domain imaging.

Authors:  S Yun; G Tearney; Johannes de Boer; N Iftimia; B Bouma
Journal:  Opt Express       Date:  2003-11-03       Impact factor: 3.894

2.  Quantitative measurement of attenuation coefficients of weakly scattering media using optical coherence tomography.

Authors:  Dirk Faber; Freek van der Meer; Maurice Aalders; Ton van Leeuwen
Journal:  Opt Express       Date:  2004-09-20       Impact factor: 3.894

3.  Comparison of retinal nerve fiber layer thickness measurements by spectral-domain optical coherence tomography systems using a phantom eye model.

Authors:  Roy de Kinkelder; Daniel M de Bruin; Frank D Verbraak; Ton G van Leeuwen; Dirk J Faber
Journal:  J Biophotonics       Date:  2012-07-19       Impact factor: 3.207

4.  Global increases in kidney cancer incidence, 1973-1992.

Authors:  A Mathew; S S Devesa; J F Fraumeni; W-H Chow
Journal:  Eur J Cancer Prev       Date:  2002-04       Impact factor: 2.497

5.  Volumetric in vivo visualization of upper urinary tract tumors using optical coherence tomography: a pilot study.

Authors:  Mieke T J Bus; Berrend G Muller; Daniel M de Bruin; Dirk J Faber; Guido M Kamphuis; Ton G van Leeuwen; Theo M de Reijke; Jean J M C H de la Rosette
Journal:  J Urol       Date:  2013-08-13       Impact factor: 7.450

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  Optical coherence tomography in vulvar intraepithelial neoplasia.

Authors:  Ronni Wessels; Daniel M de Bruin; Dirk J Faber; Hester H van Boven; Andrew D Vincent; Ton G van Leeuwen; Marc van Beurden; Theo J M Ruers
Journal:  J Biomed Opt       Date:  2012-11       Impact factor: 3.170

8.  Detection of tumorigenesis in urinary bladder with optical coherence tomography: optical characterization of morphological changes.

Authors:  T Xie; M Zeidel; Yingtian Pan
Journal:  Opt Express       Date:  2002-12-02       Impact factor: 3.894

9.  Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.

Authors:  Sherri M Donat; Mireya Diaz; Jay Todd Bishoff; Jonathan A Coleman; Philipp Dahm; Ithaar H Derweesh; S Duke Herrell; Susan Hilton; Eric Jonasch; Daniel W Lin; Victor E Reuter; Sam S Chang
Journal:  J Urol       Date:  2013-05-07       Impact factor: 7.450

10.  Quantitative comparison of the OCT imaging depth at 1300 nm and 1600 nm.

Authors:  V M Kodach; J Kalkman; D J Faber; T G van Leeuwen
Journal:  Biomed Opt Express       Date:  2010-07-16       Impact factor: 3.732

View more
  5 in total

Review 1.  Treatment approaches to small renal masses in patients of advanced age (≥75 years).

Authors:  Muhammet Fuat Özcan; Serkan Altınova; Ali Atan
Journal:  Turk J Urol       Date:  2018-07

Review 2.  Update on Renal Mass Biopsy.

Authors:  Miki Haifler; Alexander Kutikov
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

3.  Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer.

Authors:  B G Muller; A Swaan; D M de Bruin; W van den Bos; A W Schreurs; D J Faber; E C H Zwartkruis; L Rozendaal; A N Vis; J A Nieuwenhuijzen; R J A van Moorselaar; T G van Leeuwen; J J M C H de la Rosette
Journal:  Technol Cancer Res Treat       Date:  2016-07-07

4.  Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A).

Authors:  Abel Swaan; Christophe K Mannaerts; Matthijs Jv Scheltema; Jakko A Nieuwenhuijzen; C Dilara Savci-Heijink; Jean Jmch de la Rosette; R Jeroen A van Moorselaar; Ton G van Leeuwen; Theo M de Reijke; Daniel Martijn de Bruin
Journal:  JMIR Res Protoc       Date:  2018-05-21

5.  Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review.

Authors:  Oliver Brunckhorst; Qi Jia Ong; Daniel Elson; Erik Mayer
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.